[{"data":1,"prerenderedAt":161},["ShallowReactive",2],{"content-route-/en/research/erfaninejad-vvc-adherence-qualitative-2022":3},{"state":4,"owner":4,"route":5,"locale":6,"template":7,"content":21,"projection":143,"alternates":152},"target","/en/research/erfaninejad-vvc-adherence-qualitative-2022","en-US",{"kind":8,"family":8,"sectionKeys":9},"research-summary",[10,11,12,13,14,15,16,17,18,19,20],"bottom-line","why-source-matters","study-population","tested","results","applicability","limitations","contribution","practical-change","funding-conflicts","source",{"kind":8,"title":22,"description":23,"firstPublished":24,"evidenceAsOf":24,"lastUpdated":24,"changeNote":25,"research":26,"relations":57,"body":61},"Treatment concerns in recurrent vaginal yeast infection","A qualitative study interviewed 24 women with prior treatment failure and two gynecologists in Ahvaz about beliefs and concerns, not rates or route effects.","2026-10-08","First publication of the contextual S006 study summary; no claim or practical guidance changed.",{"sourceId":27,"studyType":28,"population":29,"sampleScale":30,"contribution":31,"contributionRationale":32,"relatedEvidenceMap":33,"funding":34,"conflicts":35,"paperDate":36,"results":37,"applicability":40,"limitations":46,"practicalChange":56},"erfaninejad-vvc-adherence-qualitative-2022","Qualitative interview study using inductive conventional content analysis","24 women with VVC confirmed by Pap test and prior treatment failure, described by the authors as recurrent VVC, plus two gynecologists in Ahvaz, Iran","26 interviewees: 24 women and two gynecologists; women were recruited by purposive maximum-variation sampling","contextual","The selected recurrent/treatment-failure sample offers context about beliefs and concerns raised around treatment, but themes have no prevalence denominator and the study did not measure adherence or compare routes. It cannot estimate rates, establish causality or route superiority, or change practical guidance.","/en/research/evidence/acute-vaginal-yeast-treatment","The Student Research Committee of Ahvaz Jundishapur University of Medical Sciences supported the study (reference IR.AJUMS.REC.1399.141; project 99s1).","The authors reported no competing interests.","2022-12-21",[38,39],"The authors grouped accounts into two main categories, patient beliefs and patient fears and concerns. Examples included doubts about drug effectiveness, beliefs that pills were stronger than topical cream, fear of side effects or examination, and worries about recurrence.","Participants described some concerns as barriers, such as incomplete medication use or delayed examination; fear of recurrence or future procedures could also motivate careful use.",{"appliesTo":41,"doesNotApplyTo":43},[42],"Possible treatment beliefs and concerns described by women with prior VVC treatment failure and gynecologists in Ahvaz.",[44,45],"Uncomplicated acute VVC in the general population, or how common any theme is.","A quantitative or objective adherence measure, a causal effect, a comparison of oral and vaginal treatment, or a time-to-relief estimate.",[47,50,53],{"finding":48,"limitation":49},"Interviews came from 24 selected women with prior treatment failure and two gynecologists in one city in Iran.","Purposive recruitment and local social context limit transferability; the findings do not represent all people with VVC.",{"finding":51,"limitation":52},"Participants described beliefs and fears as possible barriers or facilitators.","Themes have no prevalence denominator; the study included no comparator, quantitative adherence measure, or objective adherence verification.",{"finding":54,"limitation":55},"The interviews explored treatment experience and recurrence concerns.","No route-specific outcome or symptom-relief time was measured, so the study cannot establish rates, causality, or route superiority.","No practical change. This study does not measure adherence, establish a causal effect, or show that oral or vaginal treatment improves adherence or speeds symptom relief.",[58],{"group":59,"route":33,"label":60},"evidence","Acute vaginal yeast infection treatment evidence map",{"type":62,"value":63,"toc":139},"minimark",[64,72,78,84,90,96,102,108,114,120,126],[65,66,68],"content-section",{"section-key":10,"title":67},"Bottom line",[69,70,71],"p",{},"Interviews in Ahvaz describe beliefs and concerns around treatment among 24 women with prior treatment failure or recurrent VVC and two gynecologists. They suggest possible barriers and facilitators, but do not estimate how common they are or compare treatment routes.",[65,73,75],{"section-key":11,"title":74},"Why this source matters",[69,76,77],{},"The study records patient and clinician perspectives that can add context to a question about treatment burden. Its selected recurrent/treatment-failure sample and qualitative design do not establish adherence rates or route effects.",[65,79,81],{"section-key":12,"title":80},"Study and population",[69,82,83],{},"This descriptive qualitative study interviewed 24 women whose VVC had been confirmed by Pap test and who had prior treatment failure, plus two gynecologists, in Ahvaz, Iran. The authors described prior failure as recurrent VVC; the study took place from September 2020 to January 2021 and used purposive maximum-variation sampling.",[65,85,87],{"section-key":13,"title":86},"What was studied",[69,88,89],{},"Researchers used in-depth interviews and field notes to ask what participants thought influenced treatment use, failure, and recurrence. No treatment was assigned and no oral-versus-vaginal comparator was used.",[65,91,93],{"section-key":14,"title":92},"Results",[69,94,95],{},"The authors grouped accounts into beliefs and fears or concerns. Examples included doubts about medication effectiveness, a belief that pills were stronger than topical cream, concern about side effects or examination, and worry about recurrence. Some concerns were described as barriers, while fear of recurrence or future procedures could motivate careful use. The paper does not give prevalence denominators for the themes or measure adherence quantitatively.",[65,97,99],{"section-key":15,"title":98},"Applicability",[69,100,101],{},"These accounts apply to the selected women with prior treatment failure and the two gynecologists interviewed in Ahvaz. They do not establish what people with uncomplicated acute VVC experience generally, how frequent any concern is, or whether one route changes adherence or symptom-relief time.",[65,103,105],{"section-key":16,"title":104},"Limitations",[69,106,107],{},"The study came from one city and a purposively selected group with prior treatment failure; local social context and participant selection limit transferability. It had no comparator, objective or quantitative adherence measure, route-specific outcome, or time-to-relief estimate. The themes have no prevalence denominator and cannot establish rates, causes, or route superiority.",[65,109,111],{"section-key":17,"title":110},"Contribution to the evidence",[69,112,113],{},"This study is contextual. It offers examples of beliefs and concerns reported by a selected recurrent/treatment-failure group, but does not show how often they occur or whether they cause treatment nonadherence.",[65,115,117],{"section-key":18,"title":116},"Practical change",[69,118,119],{},"No practical change. The study does not support a new treatment recommendation or a preference for oral or vaginal treatment.",[65,121,123],{"section-key":19,"title":122},"Funding and conflicts",[69,124,125],{},"The Student Research Committee of Ahvaz Jundishapur University of Medical Sciences supported the study (reference IR.AJUMS.REC.1399.141; project 99s1). The authors reported no competing interests.",[65,127,129],{"section-key":20,"title":128},"Source",[69,130,131,138],{},[132,133,137],"a",{"href":134,"rel":135},"https://pmc.ncbi.nlm.nih.gov/articles/PMC9767851/",[136],"nofollow","Read the original publication"," (published 21 December 2022).",{"title":140,"searchDepth":141,"depth":141,"links":142},"",2,[],{"sources":144,"claims":150,"safety":151},[145],{"sourceId":27,"title":146,"canonicalId":147,"canonicalUrl":134,"publisher":148,"sourceType":149,"publicationDate":36,"lastChecked":24},"Barriers and facilitators of adherence to treatment among women with vulvovaginal candidiasis: a qualitative study","PMID:36539841; DOI:10.1186/s40001-022-00938-y","European Journal of Medical Research","observational-study",[],[],[153,156,159],{"rel":154,"hreflang":6,"href":155},"alternate","https://candipedia.org/en/research/erfaninejad-vvc-adherence-qualitative-2022/",{"rel":154,"hreflang":157,"href":158},"pl-PL","https://candipedia.org/pl/research/erfaninejad-przestrzeganie-leczenia-grzybicy-pochwy-2022/",{"rel":154,"hreflang":160,"href":155},"x-default",1791487498283]